Mersana Therapeutics

Mersana Therapeutics

A biopharmaceutical company focused on the development of oncology therapeutics

Mersana Therapeutics is a publicly traded, clinical-stage biopharmaceutical company based in Cambridge, Massachusetts that was founded in 2001 by David R. Emaleh. Using its proprietary ADC platform, the company develops highly targeted drugs with increased tolerability and expanded opportunities to deliver clinical benefits to cancer patients.

Products

XMT-1536

Mersana's lead product candidate is XMT-1536, a Dolaflexin ADC targeting NaPi2B-expressing tumors. It entered clinical development in December 2017 and is in Phase 1 clinical trials in the dose escalation phase, as of January 2019.

XMR-1522

Another product candidate's clinical development, XMR-1522, a Dolaflexin ADC targeting HEr2-expressing tumors, was discontinued in January 2019 following strategic evaluation of the program.

Partnerships

Synnafix

In January 2019, Mersana entered into a license agreement with Synnafix, a Dutch biotechnology company, to obtain access to Synaffix's GlycoConnect ADC technology. GlycoConnect is a platform technology utilizing proprietary enzymes and metal-free click conjugation to stably attach payloads specifically to the native glycan of any antibody, a privileged site for ADC applications.

Funding

Venture

On November 8, 2005 Mersana Therapeutics completed a venture capital round with 421 million in funding from ProQuest Investments (lead investor), F-Prime Capital Partners (lead Investor), Rho Capital Partners, PureTech Health, Lansing Brown Investments, Eight Roads Ventures, Cape Family Fund, and 180 degree Capital.

Series A

On April 8, 2014 Mersana Therapeutics completed their series A funding round with $14.5 million in funding from New Enterprise Associates and F-Prime Capital Partners.

Series B

On March 2, 2015 Mersana Therapeutics completed their series B funding round with $35 million in funding from New Enterprise Associates (lead investor), Rock Springs Capital, Pfizer Venture Investments, F-Prime Capital Partners, and Elliott Sigal.

Timeline

January 2019

Synnafix partnership

In January 2019, Mersana entered into a license agreement with Synnafix, a Dutch biotechnology company, to obtain access to Synaffix's GlycoConnect ADC technology.

March 29, 2015

Series B funding round

On March 2, 2015 Mersana Therapeutics completed their series B funding round with $35 million in funding from New Enterprise Associates (lead investor), Rock Springs Capital, Pfizer Venture Investments, F-Prime Capital Partners, and Elliott Sigal.

April 8, 2014

Series A funding round

On April 8, 2014 Mersana Therapeutics completed their series A funding round with $14.5 million in funding from New Enterprise Associates and F-Prime Capital Partners.

November 8, 2005

Venture funding round

On November 8, 2005 Mersana Therapeutics completed a venture capital round with 421 million in funding from ProQuest Investments (lead investor), F-Prime Capital Partners (lead Investor), Rho Capital Partners, PureTech Health, Lansing Brown Investments, Eight Roads Ventures, Cape Family Fund, and 180 degree Capital.

March 29, 2001

Founding of Mersana Therapeutics

Mersana Therapeutics was founded in 2001 by David R. Emaleh

Funding rounds

Funding round
Funding type
Funding round amount (USD)
Funding round date
Investment
Mersana Therapeutics funding round, November 2005
21,000,000
November 8, 2005
3 Results
Page 1 of 1
Results per page:
Powered by Golden Research Engine

People

Name
Role
LinkedIn

180 Degree Capital Corp.

Investor

Anna Protopapas

President & CEO

David A. Spellman

CFO

Dirk Huebner

Chief Medical Officer

Donna Jarlenski

VP, Clinical Operations

Elizabeth Fuller

Employee

Eva M. Jack

Chief Business Officer

John Kane

Employee

Michael Kaufman

Senior VP of Chemistry, Manufacturing, and Controls

Radha Iyengar

VP, Legal Operations

Timothy B. Lowinger

Chief Scientific Officer

Viet Schmelmer

VP, R&D Project Leadership & Portfolio Strategy

Wayne Foster

VP of Finance

Further reading

Title
Author
Link
Type
Date

MERSANA THERAPEUTICS LICENSES GLYCOCONNECT™ SITE-SPECIFIC ADC TECHNOLOGY FROM SYNAFFIX

ADC Review

Web

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
BioSpace
May 27, 2020
BioSpace
Achieved 35% objective response rate, including 10% complete response rate, and 80% disease control rate among twenty evaluable patients with ovarian cancer
BioSpace
May 15, 2020
BioSpace
Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that it will present preclinical data for XMT-1592, its Dolasynthen ADC candidate targeting NaPi2b, and its Immunosynthen STING-agonist ADC platform at the American Association for Cancer Research (AACR) 202
BioSpace
May 13, 2020
BioSpace
Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced plans to host a live conference call and webcast on Wednesday, May 27, 2020 at 8:00 a.m. ET to report interim data from the ongoing XMT-1536 Phase 1 dose expansion in patients with ovarian cancer and non-sma

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.